Brand Name Annual Report | Brandsymbol

2025 Brand Name Annual Report

FDA Brand Name Trends in 2025

A data-driven look at 100 U.S. FDA-approved proprietary names and what they reveal about similarity risk, naming strategy, and approval reality.

Download the 2025 Brand Name Annual Report Below

Why This Matters

FDA approval does not mean low risk.
And similarity screening is not a pass or fail exercise.

Each year, Brandsymbol analyzes FDA-approved proprietary names to uncover real-world patterns. These insights show how names are constructed, where similarity risk appears, and how successful programs manage it.

The 2025 Brand Name Annual Report reviews 100 FDA-approved names across NMEs, biologics, biosimilars, and vaccines to help teams make smarter naming decisions earlier.

Key Takeaways

Most approved names surface high-similarity comparators in standard screening tools
Approval outcomes rely on total risk assessment, not a single score
Approved names cluster around 7 to 8 characters
Subtle meaning outperforms literal descriptiveness
Biosimilars demand stronger sound and appearance differentiation

Naming Do’s and Don’ts

Do

  • Use similarity tools as early warning systems
  • Build broader candidate lists
  • Favor subtle, defensible meaning
  • Evaluate names in real-world use

Don't

  • Make go or no-go decisions based on one score
  • Chase ultra-short or trendy names
  • Rely on one-letter fixes
  • Encode overt benefit or superiority

Download the Report

Get the Brandsymbol 2025 Brand Name Annual Report for practical insights grounded in FDA approvals and real regulatory outcomes.

 

SFDC Account Engagement Form